NCT03904732View on ClinicalTrials.gov

Study to Develop a Prediction Model to Understand the Effect of Low-dose Aspirin on Cancer That Develops in the Colon and/or the Rectum, Diseases That Affects the Heart or Blood Vessels and Safety Outcomes in European Countries. The Study is Also Called PEACOS Model EU

CompletedOBSERVATIONAL
Enrollment

2,000,000

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Colorectal CancerCardiovascular DiseaseBleeding
Interventions
DRUG

Acetylsalicylic Acid (Aspirin, BAYE4465)

Low-dose acetylsalicylic acid, Aspirin (75-150 mg)

Trial Locations (1)

Unknown

Mimicked Population, Mimicked Population

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY